Trial Profile
A Phase 1, Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of Food On AG-120 Pharmacokinetics Following Single Oral Dose Administration To Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary)
- Indications Acute myeloid leukaemia; Cholangiocarcinoma; Glioma; Myelodysplastic syndromes; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Agios Pharmaceuticals
- 23 Apr 2019 Results assessing the effect of ethnicity, food, and itraconazole (strong CYP3A4 inhibitor) on the pharmacokinetics of ivosidenib after single oral doses in healthy subjects from three phase 1 open-label studies (NCT03071770, NCT02579707, NCT02831972 ), published in the European Journal of Clinical Pharmacology.
- 16 Mar 2019 Pooled data from 3 studies (NCT02579707, NCT02074839 and NCT02073994) presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 28 Nov 2016 Status changed from active, no longer recruiting to completed.